Theralase® Releases AGM Videos
Toronto, Ontario – June 29, 2018
Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical-stage pharmaceutical company dedicated to the research and development of light-activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations used to safely and effectively destroy cancer is pleased to announce the release of three videos presented at the completion of the Company’s Annual and Special Meeting, held at the Company’s corporate office on June 22, 2018.
The videos are as follows:
Girish Kulkarni MD, Surgeon-scientist affiliated with the Department of Surgery, Faculty of Medicine at the University of Toronto discusses the successful completion of the Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study
Michael Jewett MD, Professor of Surgery (Urology) at the University of Toronto discusses the proposed design of the Phase II NMIBC clinical study
Manjunatha Ankathatti Munegowda, Ph.D., DVM, Research Scientist, Theralase discusses the potential opportunities for the Company in regards to new oncological targets, such as Glio Blastoma Multiforme (“GBM”), a deadly form of brain cancer, and Non-Small Cell Lung Cancer (“NSCLC”)
Arkady Mandel, Interim Chief Executive Officer and Chief Scientific Officer of Theralase stated that, “Theralase is delighted to be associated with Dr. Kulkarni and Dr. Jewett and their combined expertise in the field of uro-oncology. Their experience and guidance was key in assisting Theralase to successfully complete a Phase Ib NMIBC clinical study, ending the study early after the treatment of only six patients. The Phase Ib NMIBC clinical study successfully met its primary, secondary and exploratory outcome measures of safety and tolerability, pharmacokinetics (movement and exit of drug within tissue) and efficacy, respectively, at ninety days post-treatment. The Company will report out on the exploratory endpoint of efficacy for patient five and six, when sufficient clinical data has been collected to provide this information. We are pleased with the results of our preclinical programs for our patented, rutherrin-based, Photo Dynamic Therapy (“PDT”). The preclinical data presented by Dr. Munegowda supports the opportunity to diversify Theralase’s PDT technology into the treatment of GBM and NSCLC. These results are planned to be further validated in human clinical studies.”
About Theralase® Technologies Inc.
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations to safely and effectively destroy various cancers. The Company in its Cool Laser Division designs, manufactures and distributes patented and proprietary super-pulsed cool laser technology for the treatment of knee pain, and in off-label use, the treatment of numerous nerve, muscle and joint conditions.
This news release contains “forward-looking statements” which reflect the current expectations of management of the Company’s future growth, results of operations, performance and business prospects and opportunities. Such statements include, but are not limited to, statements regarding the Company’s development and commercialization of the TLC-2000, including with respect to ongoing redesign work and regulatory clearance process for expanded claims and the Company’s development and commercialization strategy with respect to its Anti-Cancer Technology. Wherever possible, words such as “may“, “would“, “could“, “should”, “will“, “anticipate“, “believe“, “plan“, “expect“, “intend“, “estimate“, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions including with respect to the ability of the Company to successfully complete the redesign work under the proposed timeframe and scope of work or at all, the availability of financing to advance the development of the TLC-2000, the ability of the Company to secure further regulatory clearances (including with respect to expanded claims) from Health Canada and/ or the FDA with respect to the TLC-2000 under the proposed timeframe and scope or at all, the ability of the Company to achieve wider commercial distribution of the TLC-2000, the ability of the Company to execute its strategy with respect to its Anti-Cancer Technology, the ability of the Company to secure further regulatory approvals from Health Canada and/ or the FDA for its NMBIC clinical studies and the ability of the Company to finalize development of, and successfully commercialize, its Anti-Cancer Technology. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information: